Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 3:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 445 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Motor Neuron Disease, Amyotrophic Lateral Sclerosis Clear all
Recruiting Phase 2 Interventional

Mitochondrial Capacity Boost in ALS (MICABO-ALS) Trial

NCT04244630
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Antioxidants
Combination Product
Lead sponsor
Dallas VA Medical Center
Federal
Eligibility
21 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2025 · Synced Jul 23, 2026, 3:00 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Trial of Ascertaining Individual Preferences for Loved One's Role in End-of-Life

NCT01160367
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, GI Cancer, Pancreatic Cancer
Interventions
TAILORED Patient Family Decision Making, standard of care
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
431 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Jul 23, 2026, 3:00 PM EDT
Terminated Phase 2 Interventional Results available

Study of Safety and Proof of the Mechanism of BLZ945 in ALS Patients

NCT04066244
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
BLZ945
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
New Haven, Connecticut • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Jul 23, 2026, 3:00 PM EDT
Completed Not applicable Interventional

Humanitarian Device Exemption Post-Approval Study of NeuRx Diaphragm Pacing System for Amyotrophic Lateral Sclerosis

NCT01605006
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
NeuRx Diaphragm Pacing System (DPS)
Device
Lead sponsor
Synapse Biomedical
Industry
Eligibility
21 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2020 · Synced Jul 23, 2026, 3:00 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Clinical Trial of Ezogabine (Retigabine) in ALS Subjects

NCT02450552
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Ezogabine, Placebo
Drug
Lead sponsor
Brian Wainger
Other
Eligibility
18 Years to 80 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angeles, California • Orange, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Jul 23, 2026, 3:00 PM EDT
Completed Phase 2 Interventional Results available

Multiple Doses of AT-1501-A201 in Adults With ALS

NCT04322149
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
AT-1501
Drug
Lead sponsor
Anelixis Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
12
States / cities
Phoenix, Arizona • Orange, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Jul 23, 2026, 3:00 PM EDT
Not listed Phase 2 Interventional

Dose Escalation and Safety Study of Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis

NCT01730716
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Human spinal cord stem cell implantation
Device
Lead sponsor
Neuralstem Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Atlanta, Georgia • Boston, Massachusetts • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 19, 2015 · Synced Jul 23, 2026, 3:00 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

PatientSpot Formerly Known as ArthritisPower

NCT03840928
View directory record Official record
Conditions
Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout, Crohn Disease, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Myositis, Osteoarthritis, Osteoporosis, Psoriasis, Psoriatic Arthritis, Scleroderma, Dermatomyositis, Inflammatory Bowel Diseases, Polymyositis, Axial Spondyloarthritis, Diffuse Idiopathic Skeletal Hyperostosis, Polymyalgia Rheumatica, Giant Cell Arteritis, Temporal Arteritis, Wegener, Relapsing Polychondritis, Undifferentiated Connective Tissue Disease, Spinal Cord Injuries, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Epilepsy, Guillain-Barre Syndrome, Headache, Head Injury, Hydrocephalus, Lumbar Disc Disease, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Neurocutaneous Syndromes, Parkinson Disease, Stroke, Cluster Headache, Tension-Type Headache, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer, Cystic Fibrosis, Sleep Apnea, Eczema, Alopecia, Chronic Inflammation, Unstable Angina, Heart Attack, Heart Failure, Arrythmia, Valve Heart Disease, High Blood Pressure, Congenital Heart Disease, Peripheral Arterial Disease, Diabetes, Chronic Liver Disease, Obesity
Interventions
Not listed
Lead sponsor
Global Healthy Living Foundation
Other
Eligibility
19 Years and older
Enrollment
40,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Upper Nyack, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Jul 23, 2026, 3:00 PM EDT
Completed Not applicable Interventional Results available

The Use of Airway Clearance Devices in ALS

NCT02682030
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
High Frequency Chest Compression Device (HFCC), Cough Assist
Device
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 24, 2020 · Synced Jul 23, 2026, 3:00 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS)

NCT03268603
View directory record Official record
Conditions
ALS, Amyotrophic Lateral Sclerosis
Interventions
Autologous Adipose-derived Mesenchymal Stromal Cells
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Jul 23, 2026, 3:00 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Amyotrophic Lateral Sclerosis (ALS) Tissue Donation Program

NCT00716131
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Neurodegenerative Disease, Motor Neuron Disease
Interventions
Not listed
Lead sponsor
Drexel University College of Medicine
Other
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 5, 2017 · Synced Jul 23, 2026, 3:00 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Study to Evaluate the Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Upper or Lower Extremity Muscles Most Affected in Subjects With ALS

NCT03338114
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Fasciculation
Interventions
FLX-787-ODT (orally disintigrating tablet)
Drug
Lead sponsor
Flex Pharma, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Jul 23, 2026, 3:00 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Establishment of a Tissue Bank (Blood, CSF) for the Understanding of Motor Neuron Disease (MND)

NCT01950910
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
766 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2020
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 10, 2022 · Synced Jul 23, 2026, 3:00 PM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS)

NCT05237284
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
SAR443820, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
17
States / cities
La Jolla, California • Los Angeles, California • Orange, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Jul 23, 2026, 3:00 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Cervical Spinal Cord Metabolism and Microstructure in Amyotrophic Lateral Sclerosis(ALS)

NCT02000713
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
MRI, Clinical Exam
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 3, 2018 · Synced Jul 23, 2026, 3:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First in Human Study of ORT247 in Healthy Volunteers

NCT06769620
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
ORT247, Placebo
Drug
Lead sponsor
Orthogonal Neuroscience Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Jul 23, 2026, 3:00 PM EDT
Completed Phase 3 Interventional Results available

Escitalopram (Lexapro) for Depression MS or ALS

NCT00965497
View directory record Official record
Conditions
Major Depression, Multiple Sclerosis, Amyotrophic Lateral Sclerosis
Interventions
escitalopram
Drug
Lead sponsor
University of South Carolina
Other
Eligibility
18 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Jul 23, 2026, 3:00 PM EDT
Completed Phase 2 Interventional Results available

Safety and Biomarker Study of EPI-589 in Participants With Amyotrophic Lateral Sclerosis (ALS)

NCT02460679
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
EPI-589
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
21 Years to 70 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Los Angeles, California • San Francisco, California • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 13, 2020 · Synced Jul 23, 2026, 3:00 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Meals Study for Amyotrophic Lateral Sclerosis and Parkinson's Disease

NCT07625605
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS), Parkinson's Disease (PD)
Interventions
The MIND diet
Behavioral
Lead sponsor
The University of Tennessee, Knoxville
Other
Eligibility
30 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
3
States / cities
Elizabethton, Tennessee • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 23, 2026, 3:00 PM EDT
Completed Phase 1 Interventional Results available

Ph1 T-Regulatory Cells in Amyotrophic Lateral Sclerosis

NCT03241784
View directory record Official record
Conditions
ALS (Amyotrophic Lateral Sclerosis)
Interventions
Autologous T-regulatory lymphocytes, Interleukin-2
Biological
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 23, 2026, 3:00 PM EDT
Terminated Phase 3 Interventional

Continuation Study for Latozinemab

NCT06111014
View directory record Official record
Conditions
Neurodegenerative Diseases
Interventions
Latozinemab
Drug
Lead sponsor
Alector Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
5
States / cities
Phoenix, Arizona • Rochester, Minnesota • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Jul 23, 2026, 3:00 PM EDT
Recruiting No phase listed Observational

Impact of Physical Functioning on Patient-Reported Outcomes in ALS Patients at TidalHealth

NCT07491484
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Interventions
Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised, Amyotrophic Lateral Sclerosis Assessment Questionnaire-40
Other
Lead sponsor
TidalHealth, Inc.
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Salisbury, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Jul 23, 2026, 3:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dexpramipexole and Cimetidine Drug Drug Interaction (DDI)

NCT01536249
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Dexpramipexole, Cimetidine plus Dexpramipexole
Drug
Lead sponsor
Knopp Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 24, 2014 · Synced Jul 23, 2026, 3:00 PM EDT
Recruiting Phase 2 Interventional

Study of COYA 302 for the Treatment of ALS

NCT07161999
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
COYA 302, Placebo
Drug
Lead sponsor
Coya Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
21
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jul 23, 2026, 3:00 PM EDT